帕瑞昔布钠用于口腔颌面外科术后镇痛的临床观察被引量：1

下载PDF

导出

摘要目的探讨静脉注射帕瑞昔布钠用于口腔颌面外科术后镇痛的临床效果和安全性。方法选择ASAⅠ～Ⅱ级择期口腔颌面外科手术全麻患者60例,随机分为两组(每组30例)。手术结束前分别静注帕瑞昔布钠40mg(P组)或等量生理盐水(C组)。用视觉模拟评分法(VAS评分)分别对两组患者术后2、6、12、24h进行疼痛评分,观察并记录患者术后可能出现的不良反应,镇痛结束后统计患者对镇痛治疗的总体满意度。结果术后12h内P组患者的VAS评分明显低于C组,两组比较差异有统计学意义(P<0.05)。P组患者术后不良反应的发生率与C组比较亦明显降低,P组患者术后镇痛满意度明显高于C组,差异有统计学意义(P<0.05)。结论口腔颌面外科患者术后静注帕瑞昔布钠40mg具有良好的术后镇痛效果,而且减少了术后不良反应的发生,患者满意度高。

作者梁玉寿陈治军

机构地区泰山医学院附属邹平医院麻醉科华中科技大学同济医学院附属同济医院麻醉科

出处《重庆医学》 CAS CSCD 北大核心 2013年第11期1283-1284,共2页 Chongqing medicine

关键词术后镇痛口腔外科手术帕瑞昔布钠

分类号 R782.054 [医药卫生—口腔医学]

引文网络
相关文献

参考文献8

1Swift JQ. Nonsteroidal anti-inflammatory drugs and opioids:safety and usage concerns in the differential treatment of postoperative orofacial pain[J]. J Oral Maxillofac Surg,2000,58(10 Suppl 2) :8-11.
2Zuniga JR. Guidelines for anxiety control and pain management in oral and maxillofacial surgery[J]. J Oral Maxillofac Surg,2000,58(10 Suppl 2) :4-7.
3Reuben SS, Ekman EF, Raghunathan K, et al. The effect of eyclooxygenase-2 inhibition on acute and chronic donorsite pain after spinal-fusion surgery[J]. Reg Anesth Pain Med,2006,31(1):6-13.
4Penning TD, Talley JJ, Berteushaw SR, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclcooxygenuse-2 inhibitors: identification of 4-[5-( 4- meth ylphenyl )-3-( trifluoremethyl )-1H-pyrazol-1-yl benzenesulfonamide ( SC-58635, celecoxib ) [J]. J Med Chem, 1997,40(9) : 1347-1365.
5吴新民,岳云,张利萍,王俊科,艾登滨,于布为,薛张纲,黄文起.术后镇痛中帕瑞昔布钠对吗啡用量的节俭作用和安全性—前瞻性、多中心、随机、双盲、安慰剂对照、平行分组研究[J].中华麻醉学杂志,2007,27(1):7-10. 被引量：367
6Jirarattanaphochai K,Thienthong S, Sriraj W, et al. Effect of parecoxib on postoperative pain after lumbar spine surgery: a bicenter, randomized, double-blinded, placebo-controlled trial[J]. Spine,2008,33(2):132-139.
7Nussmeier NA, Whelton AA,Brown MT, et al. Safety and efficacy of the cyelooxygenase-2 inhibitors parecoxib and valdecoxih after noncardiac surgery[J]. Anesthesiology, 2006,104(3) : 518-526.
8Viscusi ER, Gimbel JS, Halder AM, et al. A multiple-day regimen of parecoxib sodium 20 mg twice daily provides pain relief after total hip arthroplasty[J]. Anesth Analg, 2008,107(2) :652-660.

二级参考文献11

1McArdle P. Intravenous analgesia. Crit Care Clin, 1999,15:89-104.
2Bowdle TA. Adverse effects of opioid agonists and agonist-antagonists in anesthesia. Drug Saf, 1998,19:173-189.
3Kehlet H, Dahl JB. The value of "multimodal" or "balanced analgesia"in postoperative pain treatment. Anesth Analg, 1993,77:1048-1056.
4Power I, Barrett S. Analgesic agents for the postoperative period: nonopioids. Surg Clin North Am, 1999,79:275-295.
5Tong D, Chung F. Postoperative pain control in ambulatory surgery. Surg Clin North Am, 1999,79:401-430.
6Lipsky LP, Abramson SB, Crefford L, et al. The classification of cyclooxygenase inhibitors. J Rheumatol, 1998,25:2298-2303.
7Penning TD, Talley JJ, Berteushaw SR, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenuse-2 inhihitors:identification of 4- [ 5- ( 4-methylphenyl ) -3- ( trifluoremethyl )- 1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem, 1997,40:1347-1365.
8Tang J, Li S, White PF, et al. Effect of parecoxib, a novel intravenous cyclooxygenuse type-2 inhibitor, on the postoperative opioid requirement and quality of pain control. Anesthesiology, 2002,96: 1305-1309.
9Malan TP Jr,Marsh G, Hakki SI, et al. Parecoxib sodium, a parenteral cyclooxygenuse 2 selective inhibitor, improves morphine analgesia and is opioid-sparing following total hip arthroplasty. Anesthesiology, 2003,98 :950-956.
10Kranke P, Morin AM, Roewer N, et al. Patients' global evaluation of analgesia and safety of injected parecoxib for postoperative pain: a quantitative systematic review. Anesth Analg, 2004,99:797-806.